Vyalev - antiparkinson agents
Ended Awarded Last action
- Contract number
- 36C26025F0216
- Awardee
-
Abbvie US LLC UEI MAB9Y43Z1US6
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $62,185
Award facts
- Contract value 100% obligated
- $62,185.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lenexa, KS 66219, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$27,054 | |
| Funding Only Action | $27,458 | |
| Original award | $61,781 |
About this award
The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 20, awarded a $62,185.08 firm fixed-price delivery order to AbbVie US LLC on April 16, 2025, for the supply of VYALEV (levodopa-carbidopa suspension), an antiparkinson agent medication. The contract is designed to increase medication availability for newly enrolled veterans requiring Parkinson's disease treatment, with performance completion targeted for September 30, 2025. The award was issued without a set-aside designation and represents a task order under AbbVie's larger Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB) with Veterans Integrated Service Network 12, which carries a $12.1 billion ceiling and extends through June 30, 2030. Performance will take place in Shawnee, Kansas.
AbbVie US LLC, a biopharmaceutical subsidiary of AbbVie Inc. headquartered in North Chicago, Illinois, has established itself as a significant federal healthcare contractor with specialized expertise in pharmaceutical distribution to VA networks and Indian Health Service facilities. The company currently maintains multiple indefinite delivery/indefinite quantity contracts including a complementary $15 million blanket purchase agreement with the VA National Acquisition Center specifically covering DUOPA and VYALEV medications through July 31, 2026. This delivery order reflects the VA's continued reliance on AbbVie as a pre-positioned supplier for critical Parkinson's disease therapeutics across its medical center network.
Quick answers
Who was awarded contract 36C26025F0216?
36C26025F0216 was awarded to Abbvie US LLC by Veterans Integrated Service Network 20 (Veterans Health Administration) on April 16, 2025.
How much is contract 36C26025F0216 worth?
The government has obligated $62,185 on 36C26025F0216.
Is contract 36C26025F0216 an order under another contract?
Yes. 36C26025F0216 is a delivery order under 36F79718D0528, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0216 competed?
The extent of competition for 36C26025F0216 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award